Table 1.
Baseline Characteristics of the Patients
| Characteristic | TACE-L-P Group (n = 64) | TACE-L Group (n = 58) | P |
|---|---|---|---|
| Sex | 0.852 | ||
| Male | 51 (79.7%) | 47 (81.0%) | |
| Female | 13 (20.3%) | 11 (19.0%) | |
| Age (years) | 61.4 ± 9.3 | 63.2 ± 8.5 | 0.252 |
| ECOG PS | 0.621 | ||
| 0 | 12 (20.7%) | 11 (17.2%) | |
| 1 | 46 (79.3%) | 53 (82.8%) | |
| Child-Pugh class | 0.782 | ||
| A | 38 (59.4%) | 33 (56.9%) | |
| B | 26 (40.6%) | 25 (43.1%) | |
| BCLC | 0.933 | ||
| B | 26 (40.6%) | 24 (41.4%) | |
| C | 38 (59.5%) | 34 (58.6%) | |
| AFP | 0.580 | ||
| ≤400ng/mL | 31 (48.4%) | 31 (53.4%) | |
| >400ng/mL | 33 (51.6%) | 27 (46.6%) | |
| Number of tumors | 0.457 | ||
| ≤3 | 33 (51.6%) | 26 (44.8%) | |
| >3 | 31 (48.4%) | 32 (55.2%) | |
| Largest tumor size (mm) | 78.8 ± 38.3 | 73.2 ± 35.8 | 0.339 |
| PVTT | 0.782 | ||
| Yes | 26 (40.6%) | 25 (43.1%) | |
| No | 38 (59.4%) | 33 (56.9%) | |
| Hepatic vein invasion | 0.572 | ||
| Yes | 16 (25.0%) | 12 (20.7%) | |
| No | 48 (75.0%) | 46 (79.3%) | |
| Extrahepatic metastasis | 0.611 | ||
| Yes | 13 (20.3%) | 14 (24.1%) | |
| No | 51 (79.7%) | 44 (75.9%) | |
| TACE technique | 0.319 | ||
| C-TACE | 47 (73.4%) | 47 (81.0%) | |
| D-TACE | 17 (26.6%) | 11 (19.0%) | |
| Number of TACE | 2.70 ±1.32 | 2.55 ± 1.08 | 0.491 |
Note: Data were presented as n (%) or mean ± standard deviation.
Abbreviations: TACE-L-P, transarterial chemoembolization combined with lenvatinib and PD-(L)1 inhibitor; TACE-L, transarterial chemoembolization combined with lenvatinib; ECOG PS, Eastern Cooperative Oncology Group Performance Status; AFP, a-fetoprotein; TACE, transarterial chemoembolization; C-TACE, conventional transarterial chemoembolization; D-TACE, drug-eluting bead transarterial chemoembolization.